What did @drmichaelsays actually say?
The creator issued a gatekeeper challenge: if you can't explain what happens when BPC-157 stimulates VEGF in tissues beyond your target area, you shouldn't be using it. The implied argument is that VEGF upregulation, one of BPC-157's known mechanisms, carries systemic risks that most people promoting this peptide don't understand or won't discuss.
To be clear, this isn't a dosing video or a "here's how to inject" tutorial. It's a pointed warning dressed as a pop quiz. The creator specifically calls out fitness influencers and friends who casually endorse BPC-157 as "perfectly safe." That framing matters, because the question being asked is legitimate, even if the delivery is more theatrical than informative.
Does the science back this up?
Yes, with important caveats. VEGF, or vascular endothelial growth factor, is genuinely implicated in BPC-157's healing effects, and the concern about off-target stimulation is real, not manufactured.
BPC-157 has been shown in preclinical studies to upregulate VEGF expression as part of its angiogenic and tissue-repair signaling. Chang et al. (2011, Journal of Physiology-Paris) documented this in tendon healing models. The problem is that VEGF doesn't know which tissue you're trying to fix. Systemic VEGF elevation has been studied in cancer contexts, where angiogenesis supports tumor growth. Ferrara and Kerbel (2005, Nature Reviews Drug Discovery) laid out how VEGF drives pathological angiogenesis in solid tumors. So yes, the theoretical concern is that if you have an undiagnosed or early-stage neoplasm, upregulating VEGF systemically could be problematic. That said, virtually all of this evidence is animal-based. No human clinical trials on BPC-157 have been completed to establish either therapeutic benefit or systemic VEGF-related risk in humans.
What did they get wrong (or right)?
They got the mechanism right and the caution right. Raising VEGF concerns in the BPC-157 conversation is appropriate and underrepresented in the influencer space. Credit where it's due.
What they got wrong, or at least incomplete: the framing implies that knowing the VEGF answer makes BPC-157 safe to use, which does not follow. Awareness of a risk does not eliminate it. The creator says "if they can give you a good answer to this question, then go for it," which is a leap. Understanding VEGF biology doesn't tell you whether your specific dose, route of administration, health history, or concurrent conditions make this peptide appropriate for you. The deeper problem with BPC-157 isn't that people don't know what VEGF is. It's that there is no regulatory-approved human dosing framework, no long-term safety data in humans, and no standardized manufacturing oversight for the compounded versions most people are actually using. The question is smart. The implied conclusion that answering it grants you clearance to proceed is not.
What should you actually know?
BPC-157 is a synthetic peptide derived from a protein found in gastric juice. It is not FDA-approved for any human indication. Most people obtain it through compounding pharmacies or gray-market research chemical suppliers, and those two sources are not equivalent in purity, concentration, or safety profile.
The VEGF concern raised here is real but not the only concern. Other flags include: immune modulation effects that are poorly characterized in humans, potential interactions with concurrent medications, and the fact that the majority of published efficacy data comes from rodent studies, which have a troubled track record of translating to human outcomes. If you are considering BPC-157, the conversation should start with a qualified clinician who can assess your individual health context, not end with whether your influencer can spell VEGF. Telehealth platforms operating under regulatory oversight can offer that structured evaluation in a way that a TikTok comment section cannot.